BioNTech develops immunotherapies for cancer and infectious diseases. Products include FixVac candidates for various cancers, such as melanoma, prostate cancer, and breast cancer. Other products are in development for ovarian, lung, and pancreatic cancers. The company also develops prophylactic vaccines for shingles, malaria, tuberculosis, and HSV-2. BioNTech has collaborations with several companies, including Genentech, Sanofi, and Pfizer. It has a strategic partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen Africas mRNA vaccine ecosystem. The company was incorporated in 2008 and is based in Mainz, Germany.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 105.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 1.1% |
| Net Debt/EBITDA | 100.0 |